דילוג לתוכן הראשי
xMedica

NCT07570316ClinicalTrials.gov

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs

מגייסמקבל משתתפים כעת, לפי רשומת המרשם.
יצירת קשר עם המחקר

בקצרה

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is…

שלב 3דרושים 230 משתתפים35 אתרים3 מדינות

קטגוריות

רשום במרשם אחד

מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.

מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.

מתעניינים במחקר הזה?

התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-05-06; recorded start 2026-06-10
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 87 other studies in this databaseCounted from the lead sponsor named in the record (argenx)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 18 sites

  • Data monitoring committee0/7

    Data monitoring committee not stated in the record

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 230 participants (target), run at 35 sites, across 3 countries.

How this score is built
  • Enrolment23/40

    230 participants (target)

  • Site count15/25

    18 sites

  • Country count7/15

    2 countries

  • Planned duration9/10

    Planned over about 47 months

  • Sponsor scale7/10

    argenx has led 83 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

תקציר

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it. The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment. The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment. More information can be found here: https://clinicaltrials.argenx.com/vitalithy

מצבים רפואיים

  • Graves' Disease
  • Graves Disease

זכאות

זכאות
מיןהכול
גילאים18 Years – ללא מקסימום
מתנדבים בריאיםלא

זכאות כפי שנכתבה במרשם

Inclusion Criteria: * Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF. * Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels \>=ULN (upper limit of normal) at screening. * Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) \<0.1 mIU/L at screening. * Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening. Exclusion Criteria: * History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter). * History of RAI (radioactive iodine) therapy or received a total thyroidectomy. * T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received \<6 weeks before screening. * Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications. * Graves' orbitopathy/Thyroid Eye Disease (GO/TED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and/or planned corrective surgery/irradiation or medical therapy during the study.

זכאות במשפטים פשוטים

הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.

תכנון המחקר

תכנון המחקר
סוג המחקרהתערבותי
שלבשלב 3
הקצאהאקראי
מודל ההתערבותPARALLEL
מטרה ראשיתTREATMENT
הסתרהQUADRUPLE (4)
גיוסדרושים 230 משתתפים

נותן חסות ושותפים

  • argenx נותן חסות

זרועות והתערבויות

  • Part A - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

  • Part A - placebo PH20 SC PFSPLACEBO_COMPARATOR

    Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

  • Part B - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

  • Part B - placebo PH20 SC PFSEXPERIMENTAL

    Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

  • Part C - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period

התערבויות

  • ביולוגי Efgartigimod PH20 SC

    Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)

  • אחר Placebo PH20 SC

    Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS)

מדדי תוצאה

  1. מדד תוצאה ראשוני

    Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A

    Free triiodothyronine: \[fT3\]; free thyroxine: \[fT4\]; ATDs: antithyroid drugs

    מסגרת זמן Up to 24 weeks (part A)

  2. מדד תוצאה משני

    Time to becoming euthyroid off ATDs in part A

    ATDs: antithyroid drugs

    מסגרת זמן Up to 24 weeks (part A)

  3. מדד תוצאה משני

    Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A

    MMI: methimazole (also known as thiamazole); CBZ: carbimazole.

    מסגרת זמן Up to 24 weeks (part A)

  4. מדד תוצאה משני

    Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A

    ULN : upper limit of normal; ATDs: antithyroid drugs.

    מסגרת זמן Up to 24 weeks (part A)

  5. מדד תוצאה משני

    Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A

    TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs.

    מסגרת זמן Up to 24 weeks (part A)

  6. מדד תוצאה משני

    Time to becoming euthyroid off ATDs and TRAb seronegative

    ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies.

    מסגרת זמן Up to 24 weeks (part A) + up to 135 weeks

  7. מדד תוצאה משני

    Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)

    ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ: carbimazole.

    מסגרת זמן Up to 24 weeks (Part A)

  8. מדד תוצאה משני

    Time to becoming euthyroid

    מסגרת זמן Up to 24 weeks (part A) + up to 135 weeks

  9. מדד תוצאה משני

    Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)

    TSH: thyroid-stimulating hormone; LLN: lower limit of normal.

    מסגרת זמן Up to 24 weeks (part A)

  10. מדד תוצאה משני

    Percentage of participants who remain euthyroid without ATDs

    ATDs: antithyroid drug

    מסגרת זמן Up to 74 weeks (part B)

  11. מדד תוצאה משני

    Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months

    ATDs: antithyroid drug

    מסגרת זמן Up to 74 weeks (part B) + up to 135 weeks

  12. מדד תוצאה משני

    Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS

    ATDs: antithyroid drug

    מסגרת זמן Up to 72 weeks (part C)

  13. מדד תוצאה משני

    Incidence of AEs and SAEs

    AEs: adverse events ; SAEs: serious adverse events.

    מסגרת זמן Up to 135 weeks

  14. מדד תוצאה משני

    Change in ThyPRO-39 over time

    The Thyroid-Specific Patient-Reported Outcome Short Form (ThyPRO-39) 39 item version of the ThyPRO. Each item is related to a specific aspect of the participant's experience with their thyroid condition. Each item is scored on a 5-point Likert scale, and the scores are then transformed to a 0-to-100 scale. Higher scores indicate worse health status.

    מסגרת זמן Up to 135 weeks

  15. מדד תוצאה משני

    Change in PROMIS-PF10a over time

    The Patient-Reported Outcomes Measurement Information System Physical Function-10 item (PROMIS-PF10a) is a self-administered physical functioning assessment comprising 10 items that measure respondents' ability to perform common physical tasks. Scoring involves summing the numerical responses to each item; higher scores indicate better physical function.

    מסגרת זמן Up to 135 weeks

  16. מדד תוצאה משני

    Efgartigimod serum concentrations over time

    מסגרת זמן Up to 24 weeks (part A) + 72 weeks (part C)

  17. מדד תוצאה משני

    Percentage change from baseline in total IgG levels in serum over time

    IgG: immunoglobulin G

    מסגרת זמן Up to 98 weeks

  18. מדד תוצאה משני

    Percentage change from baseline in TRAb serum levels over time

    TRAb: anti-TSHR autoantibodies.

    מסגרת זמן Up to 135 weeks

  19. מדד תוצאה משני

    Incidence of ADA against efgartigimod in serum

    ADA: antidrug antibody(ies)

    מסגרת זמן Up to 24 weeks (part A) + up to 135 weeks

  20. מדד תוצאה משני

    Incidence of antibodies against rHuPH20 in plasma

    rHuPH20: recombinant human hyaluronidase PH20

    מסגרת זמן Up to 24 weeks (part A) + Up to 135 weeks

  21. מדד תוצאה משני

    Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma

    NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20.

    מסגרת זמן Up to 24 weeks (part A) + up to 135 weeks

תאריכים

תאריכים
תאריך התחלה10 ביוני 2026 (בפועל)
סיום ראשוני1 ביוני 2028 (משוער)
סיום1 במאי 2030 (משוער)
פורסם לראשונה6 במאי 2026 (בפועל)
עודכן לאחרונה3 בנובמבר 2026
התוצאות פורסמולא צוין ברשומת המרשם
המצב אומת לאחרונהספטמבר 2026

בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.

מיקומים

35 אתרים מגייסים

Georgia

Georgia
מתקןעירמדינה או אזורמצב
LLC American Hospital NetworkTbilisiמגייס
In Vitro Fertilization Center LLCTbilisiמגייס
LLC Todua ClinicTbilisiמגייס
New HospitalsTbilisiמגייס
LTD Israeli-Georgian Medical Research Clinic HealthycoreTbilisiמגייס

United Kingdom

United Kingdom
מתקןעירמדינה או אזורמצב
Queen Elizabeth Hospital (Gateshead Health NHS Foundation Trust)GatesheadTyne and Wearמגייס

United States

United States
מתקןעירמדינה או אזורמצב
Albany Medical College Community EndocrinologyAlbanyNew Yorkמגייס
University of MichiganAnn ArborMichiganמגייס
Asheville Clinical ResearchAshevilleNorth Carolinaמגייס
Profound Research LLC at Tri-City Primary CareCarlsbadCaliforniaמגייס
Research Institute of DallasDallasTexasמגייס
Metro Detroit Endocrinology CenterDearbornMichiganמגייס
Frontier Medical Center - Academy of Diabetes Thyroid and EndocrineEl PasoTexasמגייס
Profound ResearchFarmington HillsMichiganמגייס
Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park LocationFleming IslandFloridaמגייס
The Center for Diabetes and Endocrine CareFort LauderdaleFloridaמגייס
Juno ResearchHoustonTexasמגייס
Clinic of EndocrinologyHoustonTexasמגייס
Tekton Research IrvingIrvingTexasמגייס
University of Florida Jacksonville College of MedicineJacksonvilleFloridaמגייס
Truman Medical CenterKansas CityMissouriמגייס
Ilumina Medical Research LLCKissimmeeFloridaמגייס
Johnson County Clin-Trials, Inc.LenexaKansasמגייס
Biopharma Informatic, LLCMcAllenTexasמגייס
Tekton Research - McKinneyMcKinneyTexasמגייס
Southern Endocrinology Associates PAMesquiteTexasמגייס
Oceane 7 Medical & Research Center, IncMiamiFloridaמגייס
Endocrine Associates of West Village PCNew YorkNew Yorkמגייס
Diabetes Associates Medical GroupOrangeCaliforniaמגייס
Havana Research Institute LLC.PasadenaCaliforniaמגייס
Pasadena Clinical TrialsPasadenaCaliforniaמגייס
Wake Internal Medicine ConsultantsRaleighNorth Carolinaמגייס
San Jose Clinical TrialsSan JoseCaliforniaמגייס
Consano Clinical ResearchShavano ParkTexasמגייס
Alliance for Multispecialty Research, LLCWichitaKansasמגייס

מסמכי המחקר

לא צורפו מסמכים ברשומת מרשם זו.

שינויים לאורך זמן

  1. 3 בנובמבר 2026

    אתר נוסף

    3 sites added (35 total)

    3235

  2. 16 באוקטובר 2026

    אתר נוסף

    6 sites added (32 total)

    2632

  3. 22 בספטמבר 2026

    אתר נוסף

    3 sites added (26 total)

    2326

  4. 17 בספטמבר 2026

    אתר נוסף

    1 site added (23 total)

    2223

  5. 12 באוגוסט 2026

    אתר נוסף

    4 sites added (22 total)

    1822